Pfizer Inc. (PFE) vs. Eli Lilly and Company (LLY): The Growth vs. Value Play in Pharma
Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry.
Pfizer Inc (PFE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bourgeon Capital John Zaro | 372,849 | $8,978,204 | +5% | 1.32% |
| 2. | Hourglass Capital Kenneth A. Moffet | 357,348 | $8,604,940 | +3% | 1.69% |
| 3. | P.A.W. CAPITAL PARTNERS Peter A. Wright | 82,200 | $1,979,376 | -2% | 1.51% |
| 4. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 69,581 | $1,675,510 | +1% | 0.74% |
| 5. | Bailard Inc Thomas Bailard | 51,454 | $1,239,012 | +21% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.65 | 19,457 | $499,072.05 | 27,707 | 2025-02-13 | Filing | |
| $28.24 | 1,000 | $28,240.00 | 10,000 | 2024-10-30 | Filing | |
| $26.47 | 3,000 | $79,401.00 | 9,000 | 2023-12-15 | Filing | |
| $38.58 | 1,000 | $38,580.00 | 6,000 | 2023-05-08 | Filing | |
| $38.43 | 1,000 | $38,425.00 | 5,000 | 2023-05-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.70 | 2,000 | $51,400.00 | 31,397 | 2026-06-09 | Filing | |
| $25.93 | 2,500 | $64,825.00 | 11,850 | 2025-03-04 | Filing | |
| $28.66 | 5,154 | $147,713.64 | 8,582 | 2024-08-13 | Filing | |
| $40.02 | 9,912 | $396,678.24 | 9,003 | 2023-03-15 | Filing | |
| $53.96 | 4,218 | $227,603.28 | 10,846 | 2022-06-07 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,775,929 | $331,724,370 | 0.19% | |
| 2. | 11,918,197 | $286,990,186 | 0.35% | |
| 3. | 11,902,374 | $286,609,166 | 0.36% | |
| 4. | 7,612,597 | $183,311,336 | 1.63% | |
| 5. | 6,943,719 | $167,204,754 | 0.69% |
News See All
Big Pharma Is Buying Growth. Novartis (NVS) Is Betting on Its Pipeline
Biotech M&A has hit a record pace in 2026, with deal value reaching $216 billion so far this year, up from $118 billion over the same stretch last year, according to LSEG data.
8 Worst Blue Chip Stocks to Buy Now
The word “worst” here is not about business quality.
Jim Cramer’s Opinion on 14 Stocks Like Applied Aerospace and Delta Air Lines
In this article, we will look at the stocks Jim Cramer shared his opinions on during Mad Money.
Are Dividend Stocks Tax-Efficient? 10 Picks by the Financial Media
Dividend stocks can be tax-efficient, but only in a qualified sense.
10 Best Dividend Stocks Yielding at Least 5% to Buy According to Hedge Funds
Expect strong market gains heading into the second half of the year. It is a sentiment echoed by research firms on Wall Street in the aftermath of the de-escalation of tensions in the Middle East.
Is Pfizer Inc. (PFE) A Good Stock To Buy Now?
Is PFE a good stock to buy? We came across a bullish thesis on Pfizer Inc. on r/ValueInvesting by Dismal-Cancel4958. In this article, we will summarize the bulls’ thesis on PFE.
10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds
On June 9, Reuters reported that Philips' Future Health Index survey concluded that artificial intelligence improved clinical accuracy and increased patient capacity.
12 Best S&P 500 Stocks to Buy for Dividends
Dividend stocks remain a popular choice for income-focused investors. Financial experts often point to the broader market as a strong hunting ground for long-term dividend opportunities.
12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On
On May 27, Reuters reported that Biohub, a philanthropic venture formed by Meta CEO Mark Zuckerberg and Dr. Priscilla Chan, developed a global model of protein biology to speed up drug discovery.
Hedge Fund Resource Center